Last updated: 2026-09-06 12:12:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BIOMERICA INC. (BMRA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $2.31, with a market capitalization of $10.10M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.45 to $3.21. This page covers its latest market performance, valuation, price trends and company information.
$10.10M | |
$2.27 | |
$187.12 | |
$1.45 | |
$2.22 | |
51.41K | |
-- | |
-- | |
$3.21 | |
$1.45 | |
-- | |
-- |
BIOMERICA INC. (BMRA) last closed at $2.22 as of 2026-09-04 23:31:00, unchanged from the previous close of $2.22.
During the latest regular trading session, BMRA traded between $1.45 and $187.12, with a volume of 51.41K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, BIOMERICA INC. (BMRA) moved from $2.15 to $2.31, representing a gain of 7.26% ($0.16).
The stock traded between $2.21 and $2.33 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 525.29 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 48.5%
BMRA is currently trading at $2.31, placing it 48.5% of the way from its 52-week low of $1.45 to its 52-week high of $3.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 50 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BIOMERICA INC. (BMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.